<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14666">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273052</url>
  </required_header>
  <id_info>
    <org_study_id>COR103561</org_study_id>
    <nct_id>NCT00273052</nct_id>
  </id_info>
  <brief_title>COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension</brief_title>
  <official_title>A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) With Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine whether treatment with COREG MR is more effective at
      maintaining a better lipid profile than treatment with TOPROL-XL for hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Triglycerides Levels by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for triglyceride levels. Full beta quantification test performed which uses ultracentrifugation to partially separate lipoprotein classes and is the basis for the reference methods. Change = Month 6 value minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) Levels by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for HDL-C levels. Full beta Quant test performed with HDL subclasses. Change = Month 6 value minus Baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log Transformed High Sensitivity C-reactive Protein (Hs-CRP) by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for hs-CRP. Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Log Transformed Lipoprotein-associated Phospholipase A2 (LpPLA2) by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for LpPLA2 activity. Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Manual physical examination (cuff blood pressure). Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Manual physical examination. Change = Month 6 value minus Baseline value. (BPM=beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight by Treatment Group at Maintenance Month</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Manual physical examination. Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of mg/dL at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for lipid levels. Full beta Quant test performed with HDL subclasses and IDL. IDL=Intermediate density lipoproteins, LDL=Low-density lipoprotein, VLDL=Very Low density lipoprotein, HDL=High-density lipoprotein. Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of g/L at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for lipid levels. Full beta Quant test performed. Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin (Glycemic Parameter) by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (HbA1c) (Glycemic Parameter) by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in c-Peptide (Glycemic Parameter) by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostasis Model Assessment (Glycemic Parameter) by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) (Glycemic Parameter) by Treatment Group at Maintenance Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Carvedilol Phosphate modified release formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>metoprolol succinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol Phosphate modified release formulation</intervention_name>
    <arm_group_label>Carvedilol Phosphate modified release formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol succinate</intervention_name>
    <arm_group_label>metoprolol succinate</arm_group_label>
    <other_name>Carvedilol Phosphate modified release formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented history of hypertension

          -  Triglycerides of 120-400 mg/mL

          -  LDLc levels not requiring lipid lowering medication.

        Exclusion Criteria:

          -  Has known contraindication to alpha- or beta-blocker therapy.

          -  Has taken any non-ocular beta-blockers within three months before screening.

          -  Has Type I or II diabetes.

          -  Taking lipid lowering medications.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>January 5, 2006</firstreceived_date>
  <firstreceived_results_date>December 19, 2008</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Metoprolol succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Coreg CR</title>
          <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
        </group>
        <group group_id="P2">
          <title>Toprol XL</title>
          <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening serum lipid levels</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Coreg CR</title>
          <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
        </group>
        <group group_id="B2">
          <title>Toprol XL</title>
          <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="290"/>
                <measurement group_id="B2" value="278"/>
                <measurement group_id="B3" value="568"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt; 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="260"/>
                <measurement group_id="B2" value="244"/>
                <measurement group_id="B3" value="504"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="137"/>
                <measurement group_id="B2" value="133"/>
                <measurement group_id="B3" value="270"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="153"/>
                <measurement group_id="B2" value="145"/>
                <measurement group_id="B3" value="298"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="52"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White/Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="239"/>
                <measurement group_id="B2" value="226"/>
                <measurement group_id="B3" value="465"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Triglycerides Levels by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for triglyceride levels. Full beta quantification test performed which uses ultracentrifugation to partially separate lipoprotein classes and is the basis for the reference methods. Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="235"/>
                  <measurement group_id="O2" value="206"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Triglycerides Levels by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for triglyceride levels. Full beta quantification test performed which uses ultracentrifugation to partially separate lipoprotein classes and is the basis for the reference methods. Change = Month 6 value minus Baseline value.</description>
            <units>mg/dL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.65"/>
                  <measurement group_id="O2" value="10.39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0141</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-8.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.35</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
            <estimate_desc>Median difference = Coreg CR - Toprol XL</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) Levels by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for HDL-C levels. Full beta Quant test performed with HDL subclasses. Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="235"/>
                  <measurement group_id="O2" value="206"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) Levels by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for HDL-C levels. Full beta Quant test performed with HDL subclasses. Change = Month 6 value minus Baseline value.</description>
            <units>mg/dL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-4.4"/>
                  <measurement group_id="O2" value="-5.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6068</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Mean difference = Coreg CR - Toprol XL</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log Transformed High Sensitivity C-reactive Protein (Hs-CRP) by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for hs-CRP. Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="231"/>
                  <measurement group_id="O2" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Log Transformed High Sensitivity C-reactive Protein (Hs-CRP) by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for hs-CRP. Change = Month 6 value minus Baseline value.</description>
            <units>mg/dL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.76"/>
                  <measurement group_id="O2" value="0.49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Log Transformed Lipoprotein-associated Phospholipase A2 (LpPLA2) by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for LpPLA2 activity. Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="222"/>
                  <measurement group_id="O2" value="189"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Log Transformed Lipoprotein-associated Phospholipase A2 (LpPLA2) by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for LpPLA2 activity. Change = Month 6 value minus Baseline value.</description>
            <units>mcmol/min/L</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-2.38"/>
                  <measurement group_id="O2" value="-2.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure by Treatment Group at Maintenance Month 6</title>
        <description>Manual physical examination (cuff blood pressure). Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Blood Pressure by Treatment Group at Maintenance Month 6</title>
            <description>Manual physical examination (cuff blood pressure). Change = Month 6 value minus Baseline value.</description>
            <units>mm Hg</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Systolic Blood Pressure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-15.90"/>
                  <measurement group_id="O2" value="-16.23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diastolic Blood Pressure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.89"/>
                  <measurement group_id="O2" value="-11.06"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate by Treatment Group at Maintenance Month 6</title>
        <description>Manual physical examination. Change = Month 6 value minus Baseline value. (BPM=beats per minute)</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Heart Rate by Treatment Group at Maintenance Month 6</title>
            <description>Manual physical examination. Change = Month 6 value minus Baseline value. (BPM=beats per minute)</description>
            <units>bpm</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-5.98"/>
                  <measurement group_id="O2" value="-6.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight by Treatment Group at Maintenance Month</title>
        <description>Manual physical examination. Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Weight by Treatment Group at Maintenance Month</title>
            <description>Manual physical examination. Change = Month 6 value minus Baseline value.</description>
            <units>kg</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.01"/>
                  <measurement group_id="O2" value="0.73"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of mg/dL at Maintenance Month 6</title>
        <description>Blood draw for lipid levels. Full beta Quant test performed with HDL subclasses and IDL. IDL=Intermediate density lipoproteins, LDL=Low-density lipoprotein, VLDL=Very Low density lipoprotein, HDL=High-density lipoprotein. Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of mg/dL at Maintenance Month 6</title>
            <description>Blood draw for lipid levels. Full beta Quant test performed with HDL subclasses and IDL. IDL=Intermediate density lipoproteins, LDL=Low-density lipoprotein, VLDL=Very Low density lipoprotein, HDL=High-density lipoprotein. Change = Month 6 value minus Baseline value.</description>
            <units>mg/dL</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Total Serum Cholesterol</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.1"/>
                  <measurement group_id="O2" value="-0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Low-Density Lipoprotein (LDL)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.1"/>
                  <measurement group_id="O2" value="-1.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Low+Very Low Density Lipoprotein</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9"/>
                  <measurement group_id="O2" value="0.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>High-Density Lipoprotein 2 (HDL2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.45"/>
                  <measurement group_id="O2" value="-6.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>High-Density Lipoprotein 3 (HDL3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.0"/>
                  <measurement group_id="O2" value="-3.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Low-Density Lipoprotein-Relative Flotation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.166"/>
                  <measurement group_id="O2" value="-1.360"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Intermediate Density Lipoproteins+VLDL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0"/>
                  <measurement group_id="O2" value="5.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of g/L at Maintenance Month 6</title>
        <description>Blood draw for lipid levels. Full beta Quant test performed. Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Additional Lipid Parameters by Treatment Group With Unit of Measures of g/L at Maintenance Month 6</title>
            <description>Blood draw for lipid levels. Full beta Quant test performed. Change = Month 6 value minus Baseline value.</description>
            <units>g/L</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Apolipoprotein A-1 (Apo-A1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.82"/>
                  <measurement group_id="O2" value="-3.45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Apolipoprotein B (Apo-B)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.16"/>
                  <measurement group_id="O2" value="0.81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Insulin (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
            <units>uIU/mL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.21"/>
                  <measurement group_id="O2" value="1.35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1c (HbA1c) (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Hemoglobin A1c (HbA1c) (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
            <units>Percent Change</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.01"/>
                  <measurement group_id="O2" value="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in c-Peptide (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in c-Peptide (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
            <units>ng/mL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.23"/>
                  <measurement group_id="O2" value="0.20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostasis Model Assessment (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Homeostasis Model Assessment (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
            <units>Percent Change</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.05"/>
                  <measurement group_id="O2" value="-4.14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
        <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent to Treat (ITT-E) Population was used for analysis of the efficacy results and consisted of all subjects who randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value for an efficacy parameter during the maintenance phase(number of participants will vary between measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Coreg CR</title>
            <description>Carvedilol Phosphate Extended Release 20 mg, 40 mg, and 80 mg Capsules QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>Toprol XL</title>
            <description>Metoprolol Succinate Extended Release 50 mg, 100 mg, and 200 mg Tablets QD (once daily)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                  <measurement group_id="O2" value="269"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fasting Plasma Glucose (FPG) (Glycemic Parameter) by Treatment Group at Maintenance Month 6</title>
            <description>Blood draw for glycemia levels. Full beta Quant test performed. Test for Fasting plasma glucose, HbA1c, fasting insulin. Homeostasis model Assessment (HOMA) is a computer-generated model consisting of non-linear empirical equations solved numerically to predict glucose, Insulin and C-peptide concentrations in fasting subjects for insulin sensitivity (%S). Change = Month 6 value minus Baseline value.</description>
            <units>mg/dL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.94"/>
                  <measurement group_id="O2" value="1.20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Coreg CR</title>
          <description>Results include only treatment emergent events.</description>
        </group>
        <group group_id="E2">
          <title>Toprol XL</title>
          <description>Results include only treatment emergent events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8"/>
                <counts group_id="E2" subjects_affected="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Gastroesophagael reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peridiverticular abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="186"/>
                <counts group_id="E2" subjects_affected="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
